Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 28;15:513–519. doi: 10.2147/IJN.S200505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Gao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of SANPAs treatment with and without 50-μM fructose pre-incubation on Gram-positive (A) S. aureus, (B) MRSA, and Gram-negative (C) E. coli, (D) MDR-E. coli bacteria for 4 h. The seeding density was 10⁶ CFU/mL, and x-axis shows the concentrations of SANPAs. Samples treated with peptide only are in blue, samples treated in addition with 30-min fructose pre-incubation are in red. Data was expressed by standard error of the mean (± S.E.M.), and N=3, *p<0.05 compared with control samples (0-μM peptide and 0μM fructose), **p<0.05 compared with 60-μM peptide with no fructose pre-incubation, ***p<0.05 compared with 80-μM peptide with no fructose pre-incubation, and ****p<0.05 compared with 100-μM peptide with no fructose pre-incubation.